EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Breaking Through: Immunotherapy Innovations in Pleural Mesothelioma

Amalia A Sofianidi, Nikolaos K Syrigos, Kevin G Blyth, Andriani Charpidou, Ioannis A Vathiotis

Clinical Lung Cancer · 2025-09 · 26 (6) · 458-469

DOI: 10.1016/j.cllc.2025.04.008 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Lung Cancer, 2025-09. Verfasst von Amalia A Sofianidi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Third Department of Internal Medicine, Sotiria Thoracic Diseases Hospital of Athens, National and Kapodistrian University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: Immunotherapy, Pleural Neoplasms, Immune Checkpoint Inhibitors, Mesothelioma, Malignant. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The prognosis of pleural mesothelioma (PM) is poor and conventional chemotherapy regimens have shown limited antitumor activity. Recent use of immune checkpoint inhibitors (ICIs) has shown promise, with CheckMate-743 trial establishing nivolumab plus ipilimumab as first line treatment in unresectable PM. Nevertheless, real-world applicability as well as differential benefit of immunotherapy according to histologic are areas of active debate. In addition, increased incidence of immune-related adverse events (IRAEs) and high discontinuation rates highlight the need for careful patient selection. While ICIs represent a significant advancement in PM treatment, ongoing research is necessary to refine their use, potentially through biomarker-informed approaches, and manage associated toxicities. This review highlights the evolving landscape of immunotherapy and associated controversies in PM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyPleural NeoplasmsImmune Checkpoint InhibitorsMesothelioma, MalignantMesotheliomaLung NeoplasmsHumansPrognosis

Stichwörter der Autor:innen

BiomarkersControversiesImmune checkpoint inhibitors (ICIs)

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Third Department of Internal Medicine, Sotiria Thoracic Diseases Hospital of Athens, National and Kapodistrian University of Athens, Athens, Greece.
  • School of Cancer Sciences, University of Glasgow, Glasgow, UK; Glasgow Pleural Disease Unit, Queen Elizabeth University Hospital, Glasgow, UK; Cancer Research UK Scotland Institute, Glasgow UK.
  • Third Department of Internal Medicine, Sotiria Thoracic Diseases Hospital of Athens, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: johnvat@med.uoa.gr.

Zitieren

APA

Sofianidi, A. A., Syrigos, N. K., Blyth, K. G., Charpidou, A., & Vathiotis, I. A. (2025). Breaking Through: Immunotherapy Innovations in Pleural Mesothelioma. Clinical Lung Cancer, 26(6), 458-469. https://doi.org/10.1016/j.cllc.2025.04.008

Vancouver

Sofianidi AA, Syrigos NK, Blyth KG, Charpidou A, Vathiotis IA. Breaking Through: Immunotherapy Innovations in Pleural Mesothelioma. Clinical Lung Cancer. 2025;26(6):458-469. doi:10.1016/j.cllc.2025.04.008

BibTeX
@article{Sofianidi2025,
  author = {Sofianidi, Amalia A and Syrigos, Nikolaos K and Blyth, Kevin G and Charpidou, Andriani and Vathiotis, Ioannis A},
  title = {Breaking Through: Immunotherapy Innovations in Pleural Mesothelioma},
  journal = {Clinical Lung Cancer},
  year = {2025},
  volume = {26},
  number = {6},
  pages = {458--469},
  doi = {10.1016/j.cllc.2025.04.008}
}
Kostenlos starten →